22056247|effectiveness|C1280519|start=12|end=25|CONC
22056247|advanced|C0205179|start=58|end=66|CONC
22056247|renal cell carcinoma|C2984311^C0007134^C3540608|start=67|end=87|DISO^CONC
22056247|axis|C0004457^C1522496|start=89|end=93|ANAT^CONC
22056247|phase 3|C0439561|start=109|end=116|CONC
22056247|trial|C0008976|start=117|end=122|PROC
22056247|background|C1706907|start=124|end=134|CONC
22056247|treatment|C1705169^C0039798^C1533734^C3161471^C1522326^C3538994^C0087111|start=140|end=149|PROC^CONC
22056247|advanced|C0205179|start=153|end=161|CONC
22056247|renal cell carcinoma|C2984311^C0007134^C3540608|start=162|end=182|DISO^CONC
22056247|targeted therapy|C2985566|start=210|end=226|PROC
22056247|drugs|C3687832|start=232|end=237|PROC
22056247|block|C0028778^C0332206^C1706083^C1706084^C1533157^C2828370|start=243|end=248|DISO^GEOG^OBJC^CONC
22056247|angiogenesis|C0302600^C1519670|start=249|end=261|DISO^PHYS
22056247|far|C0205108|start=266|end=269|CONC
22056247|phase 3|C0439561|start=274|end=281|CONC
22056247|effectiveness|C1280519|start=314|end=327|CONC
22056247|targeted|C0599894^C1521840|start=335|end=343|PHYS^CONC
22056247|agent|C1521826|start=344|end=349|CONC
22056247|reported|C0684224^C0700287|start=376|end=384|PROC^CONC
22056247|phase 3 study|C0282461|start=406|end=419|PROC
22056247|second|C0205436^C1561503^C0457385^C1705190^C2348168|start=463|end=469|CONC
22056247|generation|C3146294^C0079411|start=470|end=480|ACTI^CONC
22056247|inhibitor|C1999216|start=481|end=490|CONC
22056247|vascular endothelial growth factor|C1760030^C2239222|start=494|end=528|PROC^PHYS
22056247|vegf|C2349086^C2239222^C1823619|start=530|end=534|PROC^GENE
22056247|approved|C1549489^C2346846^C0205540|start=566|end=574|CONC
22056247|vegf|C2349086^C2239222^C1823619|start=575|end=579|PROC^GENE
22056247|inhibitor|C1999216|start=589|end=598|CONC
22056247|second-line therapy|C1710038|start=603|end=622|PROC
22056247|metastatic renal cell cancer|C0278678|start=640|end=668|DISO
22056247|methods|C0025664^C0449851^C0025663|start=670|end=677|CONC
22056247|included|C0332257|start=682|end=690|CONC
22056247|sites|C0205145|start=716|end=721|CONC
22056247|hospitals|C0019994^C1609061|start=723|end=732|OBJC^ORGA^CONC
22056247|outpatient clinics|C0002424|start=737|end=755|OBJC^ORGA
22056247|countries|C0454664|start=763|end=772|GEOG
22056247|aged|C0001779|start=773|end=777|PHYS
22056247|years|C0439234|start=781|end=786|CONC
22056247|confirmed|C0521093^C0750484|start=801|end=810|CONC
22056247|renal|C0022646|start=811|end=816|ANAT
22056247|carcinoma|C0007097|start=828|end=837|DISO
22056247|progressed|C1272688|start=842|end=852|CONC
22056247|first-line therapy|C1708063|start=861|end=879|PROC
22056247|containing|C2700400^C0332256|start=880|end=890|ACTI^CONC
22056247|plus|C0332287|start=914|end=918|CONC
22056247|stratified|C0205363|start=978|end=988|CONC
22056247|eastern cooperative oncology group performance status|C1520224|start=1002|end=1055|PHYS
22056247|type|C0332307^C1420009^C1552651|start=1060|end=1064|GENE^CONC
22056247|previous|C0205156^C1552607|start=1068|end=1076|CONC
22056247|treatment|C1705169^C0039798^C1533734^C3161471^C1522326^C3538994^C0087111|start=1077|end=1086|PROC^CONC
22056247|assigned|C1552601^C1516050|start=1105|end=1113|CONC
22056247|twice daily|C0585361|start=1145|end=1156|CONC
22056247|twice daily|C0585361|start=1179|end=1190|CONC
22056247|dose|C0869039^C0178602|start=1202|end=1206|CONC
22056247|increases|C0442805^C0205217|start=1207|end=1216|CONC
22056247|twice daily|C0585361|start=1244|end=1255|CONC
22056247|allowed|C0683607|start=1262|end=1269|ACTI
22056247|hypertension|C0020538|start=1297|end=1309|DISO
22056247|grade 2|C0687696^C1522446^C1883547|start=1337|end=1344|CONC
22056247|masked|C0150108^C1555580^C0150112|start=1368|end=1374|PROC^CONC
22056247|study|C0947630^C2603343^C0557651^C0008972^C1705923^C1880229|start=1378|end=1383|PROC^OBJC^CONC
22056247|treatment|C1705169^C0039798^C1533734^C3161471^C1522326^C3538994^C0087111|start=1384|end=1393|PROC^CONC
22056247|primary|C0205225^C0439631|start=1399|end=1406|PROC^CONC
22056247|endpoint|C2826544^C2349179|start=1407|end=1415|CONC
22056247|progression|C0242656^C0449258|start=1420|end=1431|DISO^CONC
22056247|free|C1996904^C1880497^C0332296|start=1432|end=1436|CONC
22056247|survival|C0038952^C0220921|start=1437|end=1445|ACTI^CONC
22056247|pfs|C0242792|start=1447|end=1450|CONC
22056247|assessed|C1516048|start=1460|end=1468|ACTI
22056247|masked|C0150108^C1555580^C0150112|start=1474|end=1480|PROC^CONC
22056247|independent|C0085862^C1608386^C1549571|start=1482|end=1493|CONC
22056247|radiology|C0807679^C1548000^C0043299^C1548429^C1962945^C0034599^C1610162^C1608525|start=1494|end=1503|OCCU^PROC^CONC
22056247|review|C1552617^C0282443|start=1504|end=1510|CONC
22056247|intention|C0162425^C1283828|start=1527|end=1536|PHYS^CONC
22056247|treat|C1292734^C1522326^C0087111|start=1540|end=1545|PROC^CONC
22056247|trial|C0008976|start=1552|end=1557|PROC
22056247|registered|C1514821|start=1562|end=1572|PROC
22056247|gov|C1419208|start=1591|end=1594|GENE
22056247|number|C1554106^C0449788^C0237753|start=1596|end=1602|CONC
22056247|findings|C2607943^C2926606^C3539655|start=1616|end=1624|PHYS^CONC
22056247|total|C0439810|start=1628|end=1633|CONC
22056247|assigned|C1552601^C1516050|start=1677|end=1685|CONC
22056247|receive|C1514756|start=1689|end=1696|CONC
22056247|median|C0876920^C2347635^C2939193^C0549183^C2348144|start=1740|end=1746|CONC
22056247|pfs|C0242792|start=1747|end=1750|CONC
22056247|months|C0439231|start=1759|end=1765|CONC
22056247|compared|C1707455|start=1780|end=1788|ACTI
22056247|months|C0439231|start=1796|end=1802|CONC
22056247|hazard ratio|C2985465|start=1819|end=1831|CONC
22056247|one-sided|C0205092|start=1859|end=1868|CONC
22056247|treatment|C1705169^C0039798^C1533734^C3161471^C1522326^C3538994^C0087111|start=1880|end=1889|PROC^CONC
22056247|toxic|C1407029^C0600688|start=1918|end=1923|DISO^CONC
22056247|effects|C1280500|start=1924|end=1931|CONC
22056247|treated with|C0332293^C1522326|start=1959|end=1971|PROC^CONC
22056247|treated with|C0332293^C1522326|start=2009|end=2021|PROC^CONC
22056247|common|C0205214^C3245511^C1522138|start=2042|end=2048|CONC
22056247|adverse events|C0877248^C1705413|start=2049|end=2063|DISO^CONC
22056247|diarrhoea|C0011991|start=2069|end=2078|DISO
22056247|hypertension|C0020538|start=2080|end=2092|DISO
22056247|fatigue|C0015672|start=2098|end=2105|DISO
22056247|arm|C1522541^C1824218^C1269612^C3715044^C1863110^C0446516^C0003798^C1140618^C1269078|start=2122|end=2125|PROC^GENE^GEOG^ANAT
22056247|diarrhoea|C0011991|start=2131|end=2140|DISO
22056247|palmar|C1184147|start=2142|end=2148|ANAT
22056247|plantar|C0442036^C0230463|start=2149|end=2156|ANAT
22056247|arm|C1522541^C1824218^C1269612^C3715044^C1863110^C0446516^C0003798^C1140618^C1269078|start=2208|end=2211|PROC^GENE^GEOG^ANAT
22056247|interpretation|C0459471^C3173575|start=2213|end=2227|PHYS^CONC
22056247|pfs|C0242792|start=2271|end=2274|CONC
22056247|compared|C1707455|start=2275|end=2283|ACTI
22056247|is a|C1292718|start=2309|end=2313|CONC
22056247|treatment option|C0683525|start=2314|end=2330|PROC
22056247|second-line therapy|C1710038|start=2335|end=2354|PROC
22056247|advanced|C0205179|start=2358|end=2366|CONC
22056247|renal cell carcinoma|C2984311^C0007134^C3540608|start=2367|end=2387|DISO^CONC
22056247|funding|C0243098^C0376244|start=2389|end=2396|CONC
22056247|pfizer|C0331888|start=2398|end=2404|ORGA
